Navigation Links
Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
Date:12/11/2011

to take hydroxyurea.

Follow-Up Study I data indicate that children who continue to take hydroxyurea have statistically lower rates of pain crises requiring emergency room visits, episodic transfusions, and hospital admissions for any reason when compared to those taking placebo. These clinical benefits are similar to those demonstrated by the drug in BABY HUG, the results of which were published earlier this year and are consistent with previously published trials that detail the therapy's benefits in older children and adults.

"Our study data reveal not only that the clinical benefits of hydroxyurea continue with ongoing administration, but also the wide acceptance of the treatment by the families of our patients, demonstrated by the high percentage of families that continued their children on hydroxyurea after the randomized trial ended," said lead author Zora R. Rogers, MD, Professor of Pediatrics at UT Southwestern Medical Center Dallas and Clinical Director of the Bone Marrow Failure and General Hematology Program at Children's Medical Center Dallas. "Analysis of growth and development assessments obtained in the Follow-Up Study along with these clinical results will further enhance our understanding of the benefits of the use of starting hydroxyurea in children with sickle cell disease at a very young age."

The BABY HUG Follow-Up Study I is funded by the National Heart, Lung, and Blood Institute (NHLBI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Dr. Rogers will present this study in an oral presentation on Sunday, December 11, at 4:30 p.m. PST at the Manchester Grand Hyatt in the Elizabeth Ballroom AB.

Genotoxicity Associated with Hydroxyurea Exposure in Infants with Sickle Cell Anemia: Results From the BABY-HUG Phase III Clinical Trial [Abstract 8]

Using data from the larg
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
2. OpenClinica EDC Solution Deployed for Retina Implant Studies
3. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
4. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
5. NIST studies how new helium ion microscope measures up
6. Five New Clinical Studies Show Value of Masimo PVI & PI
7. ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting
8. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
9. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
10. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
11. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Boston, MA (PRWEB) July 23, 2014 ... regenerative medicine transplant therapies are biological, but not ... trials may seem to treat them as if ... as well as unsanctioned studies that constitute “stem ... transplantation as an approach to developing new regenerative ...
(Date:7/22/2014)... D.C., June 22, 2014 Even within a phylum so ... is distinguished among other arthropods for its cruelty -- at ... Central America, the fly is a most predatory sort of ... cricket, deposits a smear of larvae, and leaves its wicked ... out. , None of this would be possible without ...
(Date:7/22/2014)... , July 22, 2014   BioTE Medical ... using natural, bio-identical hormone pellets, today announced the ... to the company.   Dr. Rouzier is joining the ...     Dr. Rouzier was residency trained ... and is a board certified emergency physician still ...
(Date:7/22/2014)... Wisconsin (PRWEB) July 22, 2014 ... in attendance at the 2014 NCSL International Workshop ... Booth #423 will feature CONDEC pressure instrumentation, OIML ... weights, and the new, customized sets, Essential Weights™. ... to promote cooperative efforts in solving the common ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2
... (CTI),(Nasdaq and MTA: CTIC) announced today that the ... Letter") from the Listing,Qualifications Staff (the "Staff") of ... not comply with Marketplace Rule 4350(i)(1)(C) when the,Company ... ("SMI"),and issued additional common shares to SMI shareholders. ...
... 26 Cardium Therapeutics (NYSE Alternext US: CXM) today ... from the Company,s Board of Directors. The resignation ... "We thank Dr. Simon for his service to ... the years ahead," stated Christopher J. Reinhard, Chairman and ...
... Increased 2 Percent to $15.0 Billion; Fourth Quarter 2008 ... Per Share Increased 38 Percent to $3.90; Fourth Quarter ... $0.912009 Total Revenue Expected to be in the Range ... Expected to be in the Range of $4.55 to ...
Cached Biology Technology:Cell Therapeutics Receives Additional NASDAQ Notification 2Cell Therapeutics Receives Additional NASDAQ Notification 3Cell Therapeutics Receives Additional NASDAQ Notification 4Cardium Announces Retirement of Director 2Cardium Announces Retirement of Director 3Cardium Announces Retirement of Director 4Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 2Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 3Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 4Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 5Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 6Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 7Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 8Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 9Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 10Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 11Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 12Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 13Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 14Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 15Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 16Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 17Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 18Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 19Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 20Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 21Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 22Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 23Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 24Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 25Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 26Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 27
(Date:7/22/2014)... challenges faced by researchers in modifying properties of nanomaterials ... simple technique, thanks to recent innovative studies conducted by ... Through the use of a simple, efficient and low ... research teams, led by Professor Sow Chorng Haur from ... Science, demonstrated that the properties of two different types ...
(Date:7/22/2014)... of a multinational, collaborative effort, researchers from the Icahn ... over 100 locations in the human genome associated with ... study published on any psychiatric disorder to date, conducted ... Nature , point to biological mechanisms and pathways that ... to treating the disorder, which has seen little innovation ...
(Date:7/22/2014)... in schoolyards that feature natural habitats and trees and ... and inattention, according to a University of Colorado Boulder ... such settings also provide stress-reducing benefits for youth, according ... & Place. The study is one of the ... between student access to green settings and stress. , ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3Mount Sinai scientists and international team shed new light on schizophrenia 2Mount Sinai scientists and international team shed new light on schizophrenia 3Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 2Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 3
... , June 19, 2013  Paris Air Show – ... Systems) , a leading provider of innovative test solutions ... solutions this week at the Paris Air Show ... complex armament systems with longer lifecycles, industry leaders are ...
... University, sophisticated computational models and advances in graphical processing ... genomic data, virus structure and the formation of the ... "We hope that some of what we are ... unable to replicate," says post-doctoral fellow Jason Perlmutter, first ...
... Washington, D.C. June 18, 2013 Joshua Obar, ... UniversityBozeman, has been honored with a 2013 ICAAC Young ... the regulation of immunological memory responses to infection. ... Wesleyan University in 2001 and went on to complete ...
Cached Biology News:Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Computer modeling technique goes viral at Brandeis 2The American Society for Microbiology honors Joshua Obar 2
... 1 ( Abpromise for all tested applications). ... to KLH derived from within residues 1850 to ... (Note: the amino acid sequence is proprietary) ... Entrez Gene ID: 89796 ...
Na+/H+ exchanger, isoform NHE1....
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
Biology Products: